Table 2.
Disease-related characteristics in gout patients
| Gout (n = 226) | ||
|---|---|---|
| Comorbiditiesb | ||
| Hypertension | 96 (42.5) | |
| DM | 23 (10.2) | |
| Hyperlipidemia | 25 (11.1) | |
| Cardiovascular disease | 22 (9.7) | |
| Nephropathy | 17 (7.5) | |
| Disease duration (year)C | 5 (2–12) | |
| Number of flares/last yearC | 3 (1.25–12) | |
| Stage of goutb | ||
| Asymptomatic (hyperuricemia) | 8 (3.5) | |
| Acute phase | 128 (56.6) | |
| Intercritical phase | 37 (16.4) | |
| Chronic phase | 53 (23.5) | |
| Number of tophib | ||
| No | 136 (60.2) | |
| 1 | 37 (16.4) | |
| ≥ 2 | 53 (23.5) | |
| sUA (μmol/L)a | 468.15 ± 116.59 | |
| Presence of tender joints, yesb | 190 (84.1) | |
| Presence of swollen joints, yesb | 162 (71.7) | |
| Total pain (VAS)C | 4.25(0–7.75) | |
| Urate lowering therapyb | ||
| Allopurinol | 16 (7.1) | |
| Febuxostat | 80 (35.4) | |
| Any anti-inflammatory drugsb | ||
| Colchicine | 146 (64.6) | |
| NSAID | 105 (46.5) | |
| Corticosteroids | 71 (31.4) | |
SD: standard deviation; IQR: interquartile range; DM: diabetes; NSAID: non-steroidal anti-inflammatory drugs
aMean ± SDbNumber (percentage)CMedian (IQR)